Bifogade filer
Positive study results with TrkA-NAM ACD137 against knee osteoarthritis presented at pain conference NeuPSIG 2025
Martin Jönsson CEO And Pontus Forsell Head Of D&R AlzeCure Pharma
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that its presentation at the international pain conference NeuPSIG 2025 is now available on the company's website. It includes data from preclinical studies with ACD137, the company's drug candidate in knee osteoarthritis-related pain.
“These positive data with our potent and selective TrkA-NAM, ACD137, in models of osteoarthritis, neuropathic pain and nociceptive pain further strengthen previous positive analgesic results obtained with the compound and demonstrate its utility in a variety of severe pain conditions, including osteoarthritis. In addition, ACD137 has the potential to avoid some of the side effects observed with anti-NGF antibodies due to a more selective mechanism of action,” said Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure Pharma.
The presentation, titled Analgesic and anti-inflammatory effects of ACD137, a potent and selective negative allosteric modulator of TrkA, was made by Dr. Märta Segerdahl, Chief Medical Officer at AlzeCure Pharma, and contains the results from preclinical efficacy studies with ACD137, the lead drug candidate from the TrkA-NAM project in the Painless platform.
Data from the studies show that ACD137 has potent analgesic effects in several different preclinical pain models, both in neuropathic pain and in models of osteoarthritis-related pain. The analgesic effect of ACD137 was as potent as the effect of the anti-NGF antibody Tanezumab, which has demonstrated significant and robust pain relief in several clinical trials. Furthermore, anti-inflammatory and protective effects on the knee joint were observed, something that ACD137 achieves by blocking NGF-mediated signaling via TrkA receptors, a biological mechanism with strong genetic, preclinical and clinical validation for its role in pain.
“In our TrkA-NAM program, we have identified a highly potent and selective TrkA-NAM compound, ACD137, that has significant analgesic effects in preclinical in vivo models, both in neuropathic and nociceptive pain, indicating a broad potential for the mechanism of action. There is significant and growing interest in this program among external stakeholders, especially as the mechanism of action does not have the side effects and addiction problems observed with opioids. In addition, the medical need is very high,” said Martin Jönsson, CEO of AlzeCure Pharma.
The abstract and the poster are now availaible on AlzeCure’s website (https://www.alzecurepharma.se/en/presentations-and-interviews/).